Држава: Велика Британија
Језик: Енглески
Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)
Donepezil hydrochloride
DE Pharmaceuticals
N06DA02
Donepezil hydrochloride
5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04110000
1 PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE USER ARICEPT 5 MG FILM COATED TABLETS ARICEPT 10 MG FILM COATED TABLETS Donepezil Hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any of the side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What ARICEPT is and what it is used for 2. What you need to know before you take ARICEPT 3. How to take ARICEPT 4. Possible side effects 5. How to store ARICEPT 6. Contents of the pack and other information 1. WHAT ARICEPT IS AND WHAT IT IS USED FOR ARICEPT contains the active substance donepezil hydrochloride. ARICEPT (donepezil hydrochloride) belongs to a group of medicines called acetylcholinesterase inhibitors. Donepezil increases the levels of a substance (acetylcholine) in the brain involved in memory function by slowing down the breakdown of acetylcholine. It is used to treat the symptoms of dementia in people diagnosed as having mild and moderately severe Alzheimer’s disease. The symptoms include increasing memory loss, confusion and behavioural changes. As a result, sufferers of Alzheimer’s disease find it more and more difficult to carry out their normal daily activities. ARICEPT is for use in adult patients only. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ARICEPT DO NOT TAKE ARICEPT if you are allergic to donepezil hydrochloride, or to piperidine derivatives, or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking ARICEPT if you have or have had: stomach or duodenal ulcers seizures (fi Прочитајте комплетан документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Aricept Evess 5 mg orodispersible tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains 5 mg donepezil hydrochloride, equivalent to 4.56 mg of donepezil free base. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Orodispersible tablet ARICEPT EVESS 5 mg orodispersible tablets are white, round tablets debossed ‘ARICEPT’ on one side and ‘5’ on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Aricept Evess tablets are indicated for the symptomatic treatment of: - mild to moderately severe Alzheimer’s dementia 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ _ _Adults/Elderly people_ Treatment is initiated at 5 mg/day (once-a-day dosing). The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a one- month clinical assessment of treatment at 5 mg/day, the dose of ARICEPT EVESS can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials. Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil should only be started if a caregiver is available who will regularly monitor drug intake for the patient. Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists. Therefore, the clinical benefit of donepezil should be reassessed on a regular basis. Discontinuation should be considered when evidence of a therapeutic effect is no longer present. Individual response to donepezil cannot be predicted. Upon discontinuation of treatment, a gradual abatement of the beneficial effects of ARIC Прочитајте комплетан документ